- Policy
- Will Koselugo’s reimb listing pick up speed in Korea?
- by Lee, Tak-Sun Jul 17, 2023 05:30am
- AstraZeneca is bracing up its battle to receive reimbursement approval for its Koselugo (selumetinib, AZ) within the year. The company’s new neurofibromatosis drug was unable to pass review by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee last year. AstraZeneca submitte
- Policy
- Gov’t starts researching generic drug pricing policy in 2H
- by Lee, Jeong-Hwan Jul 14, 2023 05:39am
- The Ministry of Health and Welfare has started research to improve the generic drug price system in the second half of this year. The industry expects that the authorities will likely prepare and implement a system to reduce the price of generic drugs as soon as the research is complete. The research will mainly investigate the need to ch
- Policy
- Enhertu passed the cancer dz review board after a retrial
- by Lee, Tak-Sun Jul 14, 2023 05:39am
- After a retrial in the first half of last year, the anticancer drug Enhertu, which passed the Cancer Disease Review Committee, met another hurdle: passing the Pharmaceutical Reimbursement Evaluation Committee. Enhertu, which succeeded in setting reimbursement standards at the end of the review committee's reexamination in May, was not present
- Policy
- HIRA declines NHIS and KPBMA's request
- by Lee, Tak-Sun Jul 14, 2023 05:39am
- The National Health Insurance Service and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association have requested to participate in the Drug Reimbursement Evaluation Committee, but the Health Insurance Review and Assessment Service announced plans to amend its operational regulations without reflecting their requests. The NHIS h
- Policy
- Approval of phase 3 for Retatrutide
- by Lee, Hye-Kyung Jul 14, 2023 05:38am
- Eli Lilly's anti-obesity drug Ly3437943 is undergoing phase 3 clinical trials in Korea. The Ministry of Food and Drug Safety recently approved a phase 3 clinical trial to study the efficacy and safety of once-weekly administration of Retatrutide in obese or overweight type 2 diabetic subjects. Seoul National University Hospital, Severance
- Policy
- HIRA is reviewing reimb of Korea’s first donepezil 3mg
- by Lee, Tak-Sun Jul 14, 2023 05:38am
- The 3mg donepezil tablet that was developed by Hyundai Pharmaceutical is being reviewed by the health authorities for reimbursement in Korea. No other tablet formulation of donepezil 3mg currently exists in Korea’s reimbursement list. Therefore, the Health Insurance Review and Assessment Service is seeking for the most appropriate devel
- Policy
- ‘Refer to Japan’s half-price policy for generic's price'
- by Lee, Tak-Sun Jul 13, 2023 05:35am
- The Health Insurance Research Institute, a research institution under the National Health Insurance Service, stressed the need to refer to Japan’s generic drug price reduction policies in its recently published ‘Issue & View June 2023.’ Hyun-Ok Lee, Associate Research Fellow of the Health Insurance Research Institute, and her fellow res
- Policy
- Will the number of generics decrease?
- by Lee, Tak-Sun Jul 13, 2023 05:35am
- Analysts say that the government has begun strengthening the standard for cascading drug pricing in order to reduce the number of generics. A plan to reduce the existing list of 20 items, which is currently used as the standard for lowering the upper limit of new items, to 10 seems promising. However, the industry points out that there is a l
- Policy
- 2 Tylenol products stopped production will be decided in 2Q
- by Lee, Jeong-Hwan Jul 13, 2023 05:35am
- In the second half of this year, the Ministry of Health and Welfare plans to discuss the cancellation of the safety household medicine designation and the designation of additional alternative medicines for two Tylenol items, which have stopped production due to the sale of Janssen Korea's Hyangnam plant. On the 11th, the Ministry of Health
- Policy
- Gov’s halts price cut discussions on generics
- by Lee, Jeong-Hwan Jul 10, 2023 05:21am
- Pharmaceutical companies in Korea are carefully monitoring the government's direction in improving the pricing system of generic drugs, including the government's insurance ceiling price policy. The Ministry of Health and Welfare was known to be contemplating a system with the health insurance authorities to further reduce the price of
